Federal Official Gazette
ANS NORMATIVE RESOLUTION No. 662, OF FEBRUARY 4, 2026.
Amends Annex II of Normative Resolution (RN) No. 465, of February 24, 2021, which governs the List of Health Procedures and Events (Rol) within the scope of Supplementary Health, in order to expand the care coverage of the drug Emicizumab, related to “INTRAVENOUS, INTRAMUSCULAR OR SUBCUTANEOUS IMMUNOBIOLOGICAL THERAPY (WITH USAGE GUIDELINE)”, in the prophylactic treatment of patients with severe hemophilia A or with factor VIII activity level below 2%, without factor VIII inhibitor antibodies, aged up to 6 years at the start of treatment; and to incorporate the off-label use (not described in the package insert registered with Anvisa) of the drug Methotrexate, linked to “OUTPATIENT INJECTABLE DRUG THERAPY (WITH USAGE GUIDELINE)”, for the treatment of patients of any age with moderate to severe Atopic Dermatitis, in compliance with art. 33 of RN No. 555/2022, art. 19T of Law No. 8,080/1990, as amended by Law No. 14,313/2022, and paragraphs 4 and 10 of art. 10 of Law No. 9,656/1998.
ANS news
Grupo Amil joins Agora Tem Especialistas and will serve SUS patients
During an event in Rio de Janeiro, ANS and the Ministry of Health also launched a new public call notice for health plan operators to join the program
Open public consultations
There are no open public consultations.
Scheduled public hearings
There are no scheduled public hearings.
Open public calls for input
- The Public Call for Input (TPS) is open, intended to receive suggestions on the priority Supplementary Health topics that will inform the composition of the 2026-2028 Regulatory Agenda of the National Supplementary Health Agency (ANS). Extension: February 27, 2026.
Open public calls
No updates.
Other news
– No updates.
Sources: Federal Official Gazette (DOU) and the ANS website. Press items link to the original article. This brief is for information only and does not constitute legal advice.